Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Increases By 10.5%

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 62,900 shares, a growth of 10.5% from the August 15th total of 56,900 shares. Based on an average daily volume of 187,600 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Kazia Therapeutics

An institutional investor recently raised its position in Kazia Therapeutics stock. Morgan Stanley increased its stake in Kazia Therapeutics Limited (NASDAQ:KZIA) by 25.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 257,341 shares of the company’s stock after purchasing an additional 52,891 shares during the quarter. Morgan Stanley owned about 1.85% of Kazia Therapeutics worth $158,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.05% of the company’s stock.

Kazia Therapeutics Stock Down 1.0 %

KZIA stock opened at $1.00 on Tuesday. The company has a 50-day simple moving average of $0.96 and a 200 day simple moving average of $1.11. Kazia Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $1.68.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.